Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • AGIR
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events

DEINOVE is pioneering the exploration of “microbial dark matter”

By revealing the metabolic potential of rare bacteria or still classified as uncultivable, the company tackles a global health and economic challenge:
ANTIMICROBIAL RESISTANCE

Latest news

17.11.2021

DEINOVE invites its shareholders to "Investir Day" on November 23, 2021

The first stage of the Phase II clinical trial continues despite the COVID-19 pandemic in the U.S...
Investors
30.09.2021

DEINOVE presents its financial results and the advancement of its programs for the first half of 2021

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB)...
Corporate
More press releases
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

         

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home